56 research outputs found
Fluphenazine-induced acute and tardive dyskinesias in monkeys
Five Cebus apella monkeys were treated with biweekly injections of fluphenazine enanthate (0.1–3.2 mg/kg IM). Three of these completed 1 full year of treatment, one injured its leg after 6 months of treatment and was killed, and another died of unknown causes after 9 months of treatment. All monkeys displayed abnormal movements corresponding to the early appearing extrapyramidal symptoms of neuroleptic-treated patients. These consisted initially of slowing or absence of volitional movement, trembling of the hands, trembling of the entire body, and general drowsy behavior. As treatment progessed, a variety of abnormal postures and movements appeared after each injection that were not exacerbated by drug withdrawal and, as tested at the end of the year, could be abolished or prevented with benztropine mesylate (0.2–0.5 mg/kg IM). The three monkeys that completed 1 year of treatment with fluphenazine were then withdrawn from the drug. After withdrawal, all three developed movements similar in appearance to those of patients with tardive dyskinesia (TD). Reinstitution of fluphenazine treatment, as tested in one monkey, abolished all movements resembling TD.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46432/1/213_2004_Article_BF00555204.pd
TheL-dopa on-off effect in parkinson disease: Treatment by transient drug withdrawal and dopamine receptor resensitization
Influence of peptides on reduced response of rats to electric footshock after acute administration of morphine
Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases
Coexistence of mixed phenotype Creutzfeldt-Jakob disease, Lewy body disease and argyrophilic grain disease plus histological features of possible Alzheimer's disease: A multi-protein disorder in an autopsy case
- …